HFA Premium Access

Long-term treatment with inotersen and potential improvement of amyloid transthyretin cardiomyopathy

Topic: Cardiovascular Pharmacotherapy, Other

Congress Presentation

10 more presentations in this session

Sacubitril valsartan in real life: tolerance, clinical evolution and remodeled long term

Speaker: Doctor R. Bravo-Marques (Marbella, ES)

Thumbnail

Security of neurohormonal blocking with sacubitril / valsartan, iSGLT2 and mineralocorticoid receptor antagonist in patients with heart failure with reduced eyection fraction and diabetes mellitus

Speaker: Doctor R. Bravo-Marques (Marbella, ES)

Thumbnail

Improvement of NT-proBNP and NYHA values in patients with HFrEF and Sacubitril/Valsartan treatment

Speaker: Doctor C. Goena Vives (Donostia, ES)

Thumbnail

Long-term prognostic impact of beta-blocker prescription during hospitalization for acute myocardial infarction

Speaker: Doctor F. Fonseca Goncalves (Vila Real, PT)

Thumbnail

Diabetic patients need higher loop diuretic doses: a report on acute and chronic heart failure patients

Speaker: Associate Professor P. Bettencourt (Porto, PT)

Thumbnail

Access the full session

Poster Session 1 - Pharmacology and Pharmacotherapy

Speakers: Doctor R. Bravo-Marques, Doctor R. Bravo-Marques, Doctor C. Goena Vives, Doctor F. Fonseca Goncalves, Associate Professor P. Bettencourt
Thumbnail

About the event

Image

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb